First ‐line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD‐L1: A case report

A 90 ‐year‐old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT‐guided lung biopsy revealed squamous cell carcinoma harboring anEGFR mutation. In addition, programmed death ‐ligand 1 (PD‐L1) was highly expressed with a tumor proportion score (TPS) of>75%. Pembrolizumab therapy in the first ‐line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with bothEGFR mutation and high expression of PD ‐L1 are very rare.

Source: Thoracic Cancer - April 13, 2020 Category: Cancer & Oncology Authors: Kosuke Hamai, Hiroki Tanahashi, Sayaka Ueno, Hanae Konishi, Mirai Matsumura, Akio Nomura, Kanako Nakamoto, Shoko Isoyama, Takuya Tanimoto, Hiroyasu Shoda, Nobuhisa Ishikawa Tags: CASE REPORT Source Type: research